Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer

In patients with RAS wild-type metastatic colorectal cancer (mCRC), an anti-epidermal growth factor receptor (EGFR) monoclonal antibody plus chemotherapy is a standard option for treatment in the first-line setting. Patients who progress while on treatment with anti-EGFR-based therapy can be resista...

Descripción completa

Detalles Bibliográficos
Autores principales: Cremolini, Chiara, Montagut, Clara, Ronga, Philippe, Venturini, Filippo, Yamaguchi, Kensei, Stintzing, Sebastian, Sobrero, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932317/
https://www.ncbi.nlm.nih.gov/pubmed/36818675
http://dx.doi.org/10.3389/fonc.2022.946850

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932317/
https://www.ncbi.nlm.nih.gov/pubmed/36818675
http://dx.doi.org/10.3389/fonc.2022.946850

Ejemplares similares